Comparative Medicine, Pfizer Worldwide Research, Development & Medical, Cambridge, Massachusetts, United States of America.
Comparative Medicine, Pfizer Worldwide Research, Development & Medical, Groton, Connecticut, United States of America.
PLoS One. 2021 Sep 20;16(9):e0257694. doi: 10.1371/journal.pone.0257694. eCollection 2021.
In oncology research, while xenograft tumor models are easily visualized and humane endpoints can be clearly defined, metastatic tumor models are often based on more subjective clinical observations as endpoints. This study aimed at identifying objective non-invasive criteria for predicting imminent distress and mortality in metastatic lung tumor-bearing mice. BALB/c and C57BL/6 mice were inoculated with CT26 or B16F10 cells, respectively. The mice were housed in Vium smart cages to continuously monitor and stream respiratory rate and locomotion for up to 28 days until scheduled euthanasia or humane endpoint criteria were met. Body weight and body temperature were measured during the study. On days 11, 14, 17 and 28, lungs of subsets of animals were microCT imaged in vivo to assess lung metastasis progression and then euthanized for lung microscopic evaluations. Beginning at day 21, most tumor-bearing animals developed increased respiratory rates followed by decreased locomotion 1-2 days later, compared with the baseline values. Increases in respiratory rate did not correlate to surface tumor nodule counts or lung weight. Body weight measurement did not show significant changes from days 14-28 in either tumor-bearing or control animals. We propose that increases in respiratory rate (1.3-1.5 X) can be used to provide an objective benchmark to signal the need for increased clinical observations or euthanasia. Adoption of this novel humane endpoint criterion would allow investigators time to collect tissue samples prior to spontaneous morbidity or death and significantly reduce the distress of mice in the terminal stages of these metastatic lung tumor models.
在肿瘤学研究中,虽然异种移植肿瘤模型易于可视化,并且可以明确界定人性化的终点,但转移性肿瘤模型通常基于更主观的临床观察作为终点。本研究旨在确定预测转移性肺肿瘤荷瘤小鼠即将发生的痛苦和死亡的客观非侵入性标准。BALB/c 和 C57BL/6 小鼠分别接种 CT26 或 B16F10 细胞。将小鼠饲养在 Vium 智能笼中,持续监测并流式传输呼吸率和运动长达 28 天,直到达到预定的安乐死或人性化终点标准。在研究过程中测量体重和体温。在第 11、14、17 和 28 天,对动物亚组的肺部进行活体 microCT 成像,以评估肺转移进展,然后安乐死进行肺微观评估。从第 21 天开始,与基线值相比,大多数荷瘤动物的呼吸率增加,随后 1-2 天后运动减少。呼吸率的增加与表面肿瘤结节计数或肺重量无关。在荷瘤或对照动物中,体重测量从第 14 天到第 28 天都没有明显变化。我们提出,呼吸率的增加(1.3-1.5X)可用于提供客观基准,以提示需要增加临床观察或安乐死。采用这种新的人性化终点标准将使研究人员有时间在自发性发病或死亡之前收集组织样本,并显著减少这些转移性肺肿瘤模型末期小鼠的痛苦。